{"frames":[{"target":{"name":"Craft","spans":[{"start":0,"end":1,"text":"Science"}]},"annotationSets":[{"rank":0,"score":11.691366466170551,"frameElements":[]}]},{"target":{"name":"Medical_specialties","spans":[{"start":2,"end":3,"text":"medicine"}]},"annotationSets":[{"rank":0,"score":4.571156479647906,"frameElements":[{"name":"Specialty","spans":[{"start":0,"end":3,"text":"Science translational medicine"}]}]}]}],"tokens":["Science","translational","medicine","."]}
{"frames":[{"target":{"name":"Kinship","spans":[{"start":3,"end":4,"text":"family"}]},"annotationSets":[{"rank":0,"score":21.279982352745375,"frameElements":[{"name":"Relatives","spans":[{"start":3,"end":4,"text":"family"}]}]}]},{"target":{"name":"Inspecting","spans":[{"start":6,"end":7,"text":"dissect"}]},"annotationSets":[{"rank":0,"score":43.08381406768743,"frameElements":[{"name":"Ground","spans":[{"start":7,"end":10,"text":"cell survival dependencies"}]}]}]},{"target":{"name":"Building_subparts","spans":[{"start":7,"end":8,"text":"cell"}]},"annotationSets":[{"rank":0,"score":15.356628826801959,"frameElements":[{"name":"Building_part","spans":[{"start":7,"end":8,"text":"cell"}]}]}]},{"target":{"name":"Surviving","spans":[{"start":8,"end":9,"text":"survival"}]},"annotationSets":[{"rank":0,"score":15.220875260370526,"frameElements":[]}]},{"target":{"name":"Reliance","spans":[{"start":9,"end":10,"text":"dependencies"}]},"annotationSets":[{"rank":0,"score":37.35852455780743,"frameElements":[]}]},{"target":{"name":"Communicate_categorization","spans":[{"start":11,"end":12,"text":"define"}]},"annotationSets":[{"rank":0,"score":35.15819460660212,"frameElements":[{"name":"Item","spans":[{"start":12,"end":17,"text":"improved strategies for cancer therapy"}]}]}]},{"target":{"name":"Cause_to_make_progress","spans":[{"start":12,"end":13,"text":"improved"}]},"annotationSets":[{"rank":0,"score":72.81426288591578,"frameElements":[{"name":"Project","spans":[{"start":13,"end":14,"text":"strategies"}]}]}]},{"target":{"name":"Medical_conditions","spans":[{"start":15,"end":16,"text":"cancer"}]},"annotationSets":[{"rank":0,"score":37.097026595515736,"frameElements":[]}]},{"target":{"name":"Cure","spans":[{"start":16,"end":17,"text":"therapy"}]},"annotationSets":[{"rank":0,"score":40.41124638174753,"frameElements":[]}]}],"tokens":["Exploiting","selective","BCL-2","family","inhibitors","to","dissect","cell","survival","dependencies","and","define","improved","strategies","for","cancer","therapy","."]}
{"frames":[{"target":{"name":"Evidence","spans":[{"start":8,"end":9,"text":"shown"}]},"annotationSets":[{"rank":0,"score":35.35516173048278,"frameElements":[{"name":"Proposition","spans":[{"start":9,"end":20,"text":"promising clinical activity in lymphoid malignancies such as chronic lymphocytic leukemia"}]},{"name":"Support","spans":[{"start":0,"end":4,"text":"The BCL-2/BCL-X-L/BCL-W inhibitor ABT-263"}]}]}]},{"target":{"name":"Omen","spans":[{"start":9,"end":10,"text":"promising"}]},"annotationSets":[{"rank":0,"score":29.72335218523301,"frameElements":[]}]},{"target":{"name":"Intentionally_act","spans":[{"start":11,"end":12,"text":"activity"}]},"annotationSets":[{"rank":0,"score":58.7414736612045,"frameElements":[{"name":"Manner","spans":[{"start":10,"end":11,"text":"clinical"}]},{"name":"Act","spans":[{"start":12,"end":20,"text":"in lymphoid malignancies such as chronic lymphocytic leukemia"}]}]}]},{"target":{"name":"Duration_attribute","spans":[{"start":17,"end":18,"text":"chronic"}]},"annotationSets":[{"rank":0,"score":9.159829772132984,"frameElements":[]}]},{"target":{"name":"Weapon","spans":[{"start":19,"end":20,"text":"leukemia"}]},"annotationSets":[{"rank":0,"score":46.741951823156526,"frameElements":[{"name":"Weapon","spans":[{"start":19,"end":20,"text":"leukemia"}]}]}]}],"tokens":["The","BCL-2/BCL-X-L/BCL-W","inhibitor","ABT-263","-LRB-","navitoclax","-RRB-","has","shown","promising","clinical","activity","in","lymphoid","malignancies","such","as","chronic","lymphocytic","leukemia","."]}
{"frames":[{"target":{"name":"Concessive","spans":[{"start":0,"end":1,"text":"However"}]},"annotationSets":[{"rank":0,"score":5.875789320013224,"frameElements":[]}]},{"target":{"name":"Causation","spans":[{"start":11,"end":12,"text":"caused"}]},"annotationSets":[{"rank":0,"score":62.070929845710346,"frameElements":[{"name":"Cause","spans":[{"start":10,"end":11,"text":"thrombocytopenia"}]},{"name":"Effect","spans":[{"start":12,"end":15,"text":"by BCL-X-L inhibition"}]}]}]}],"tokens":["However",",","its","efficacy","in","these","settings","is","limited","by","thrombocytopenia","caused","by","BCL-X-L","inhibition","."]}
{"frames":[{"target":{"name":"Cause_to_start","spans":[{"start":1,"end":2,"text":"prompted"}]},"annotationSets":[{"rank":0,"score":35.005026225610166,"frameElements":[{"name":"Cause","spans":[{"start":0,"end":1,"text":"This"}]},{"name":"Effect","spans":[{"start":2,"end":23,"text":"the generation of the BCL-2-selective inhibitor venetoclax -LRB- ABT-199/GDC0199 -RRB- , which demonstrates robust activity in these cancers but spares platelets"}]}]}]},{"target":{"name":"Intentionally_create","spans":[{"start":3,"end":4,"text":"generation"}]},"annotationSets":[{"rank":0,"score":43.2712079609119,"frameElements":[{"name":"Created_entity","spans":[{"start":4,"end":23,"text":"of the BCL-2-selective inhibitor venetoclax -LRB- ABT-199/GDC0199 -RRB- , which demonstrates robust activity in these cancers but spares platelets"}]}]}]},{"target":{"name":"Evidence","spans":[{"start":14,"end":15,"text":"demonstrates"}]},"annotationSets":[{"rank":0,"score":33.65986651156527,"frameElements":[{"name":"Proposition","spans":[{"start":15,"end":17,"text":"robust activity"}]},{"name":"Support","spans":[{"start":13,"end":14,"text":"which"}]}]}]},{"target":{"name":"Intentionally_act","spans":[{"start":16,"end":17,"text":"activity"}]},"annotationSets":[{"rank":0,"score":63.7611197931583,"frameElements":[]}]},{"target":{"name":"Medical_conditions","spans":[{"start":19,"end":20,"text":"cancers"}]},"annotationSets":[{"rank":0,"score":39.77184326457723,"frameElements":[]}]}],"tokens":["This","prompted","the","generation","of","the","BCL-2-selective","inhibitor","venetoclax","-LRB-","ABT-199/GDC0199","-RRB-",",","which","demonstrates","robust","activity","in","these","cancers","but","spares","platelets","."]}
{"frames":[{"target":{"name":"Evidence","spans":[{"start":4,"end":5,"text":"shown"}]},"annotationSets":[{"rank":0,"score":35.07803816735762,"frameElements":[{"name":"Proposition","spans":[{"start":5,"end":17,"text":"to enhance the efficacy of docetaxel in preclinical models of solid tumors"}]}]}]},{"target":{"name":"Cause_to_make_progress","spans":[{"start":6,"end":7,"text":"enhance"}]},"annotationSets":[{"rank":0,"score":71.4762379061811,"frameElements":[{"name":"Agent","spans":[{"start":0,"end":1,"text":"Navitoclax"}]},{"name":"Project","spans":[{"start":7,"end":11,"text":"the efficacy of docetaxel"}]}]}]},{"target":{"name":"Vehicle","spans":[{"start":13,"end":14,"text":"models"}]},"annotationSets":[{"rank":0,"score":24.917910717663858,"frameElements":[{"name":"Vehicle","spans":[{"start":13,"end":14,"text":"models"}]}]}]},{"target":{"name":"Substance","spans":[{"start":15,"end":16,"text":"solid"}]},"annotationSets":[{"rank":0,"score":28.20774230222073,"frameElements":[{"name":"Substance","spans":[{"start":15,"end":16,"text":"solid"}]}]}]},{"target":{"name":"Medical_conditions","spans":[{"start":16,"end":17,"text":"tumors"}]},"annotationSets":[{"rank":0,"score":34.09177703115916,"frameElements":[]}]},{"target":{"name":"Purpose","spans":[{"start":20,"end":21,"text":"use"}]},"annotationSets":[{"rank":0,"score":33.41784216432604,"frameElements":[{"name":"Goal","spans":[{"start":5,"end":17,"text":"to enhance the efficacy of docetaxel in preclinical models of solid tumors"}]},{"name":"Means","spans":[{"start":21,"end":24,"text":"of this combination"}]}]}]}],"tokens":["Navitoclax","has","also","been","shown","to","enhance","the","efficacy","of","docetaxel","in","preclinical","models","of","solid","tumors",",","but","clinical","use","of","this","combination","has","been","limited","by","neutropenia","."]}
{"frames":[{"target":{"name":"Using","spans":[{"start":1,"end":2,"text":"used"}]},"annotationSets":[{"rank":0,"score":103.7892504861343,"frameElements":[{"name":"Instrument","spans":[{"start":2,"end":7,"text":"venetoclax and the BCL-X-L-selective inhibitors"}]},{"name":"Agent","spans":[{"start":0,"end":1,"text":"We"}]}]}]},{"target":{"name":"Assessing","spans":[{"start":11,"end":12,"text":"assess"}]},"annotationSets":[{"rank":0,"score":91.3400842511718,"frameElements":[{"name":"Phenomenon","spans":[{"start":12,"end":29,"text":"the relative contributions of inhibiting BCL-2 or BCL-X-L to the efficacy and toxicity of the navitoclax-docetaxel combination"}]}]}]},{"target":{"name":"Kinship","spans":[{"start":13,"end":14,"text":"relative"}]},"annotationSets":[{"rank":0,"score":19.54857461649483,"frameElements":[]}]},{"target":{"name":"Giving","spans":[{"start":14,"end":15,"text":"contributions"}]},"annotationSets":[{"rank":0,"score":58.833564298373965,"frameElements":[{"name":"Theme","spans":[{"start":15,"end":29,"text":"of inhibiting BCL-2 or BCL-X-L to the efficacy and toxicity of the navitoclax-docetaxel combination"}]}]}]},{"target":{"name":"Hindering","spans":[{"start":16,"end":17,"text":"inhibiting"}]},"annotationSets":[{"rank":0,"score":48.50327539286259,"frameElements":[]}]}],"tokens":["We","used","venetoclax","and","the","BCL-X-L-selective","inhibitors","A-1155463","and","A-1331852","to","assess","the","relative","contributions","of","inhibiting","BCL-2","or","BCL-X-L","to","the","efficacy","and","toxicity","of","the","navitoclax-docetaxel","combination","."]}
{"frames":[{"target":{"name":"Explaining_the_facts","spans":[{"start":12,"end":13,"text":"accounting"}]},"annotationSets":[{"rank":0,"score":20.298176916158422,"frameElements":[{"name":"State_of_affairs","spans":[{"start":13,"end":25,"text":"for the exacerbated neutropenia observed when navitoclax was combined with docetaxel clinically"}]}]}]},{"target":{"name":"Statement","spans":[{"start":17,"end":18,"text":"observed"}]},"annotationSets":[{"rank":0,"score":101.90018052102903,"frameElements":[{"name":"Message","spans":[{"start":18,"end":25,"text":"when navitoclax was combined with docetaxel clinically"}]},{"name":"Speaker","spans":[{"start":14,"end":17,"text":"the exacerbated neutropenia"}]}]}]},{"target":{"name":"Temporal_collocation","spans":[{"start":18,"end":19,"text":"when"}]},"annotationSets":[{"rank":0,"score":24.19445037584726,"frameElements":[]}]},{"target":{"name":"Cause_to_amalgamate","spans":[{"start":21,"end":22,"text":"combined"}]},"annotationSets":[{"rank":0,"score":53.74014832975755,"frameElements":[]}]}],"tokens":["Selective","BCL-2","inhibition","suppressed","granulopoiesis","in","vitro","and","in","vivo",",","potentially","accounting","for","the","exacerbated","neutropenia","observed","when","navitoclax","was","combined","with","docetaxel","clinically","."]}
{"frames":[{"target":{"name":"Hindering","spans":[{"start":4,"end":5,"text":"inhibiting"}]},"annotationSets":[{"rank":0,"score":54.00036027619282,"frameElements":[{"name":"Action","spans":[{"start":5,"end":6,"text":"BCL-X-L"}]}]}]},{"target":{"name":"Intentionally_act","spans":[{"start":6,"end":7,"text":"did"}]},"annotationSets":[{"rank":0,"score":52.78912438982343,"frameElements":[{"name":"Act","spans":[{"start":4,"end":6,"text":"inhibiting BCL-X-L"}]}]}]},{"target":{"name":"Temporal_collocation","spans":[{"start":18,"end":19,"text":"when"}]},"annotationSets":[{"rank":0,"score":24.19445037584726,"frameElements":[]}]},{"target":{"name":"Operational_testing","spans":[{"start":19,"end":20,"text":"tested"}]},"annotationSets":[{"rank":0,"score":61.759701752482414,"frameElements":[{"name":"Product","spans":[{"start":20,"end":26,"text":"against a range of solid tumors"}]}]}]},{"target":{"name":"Range","spans":[{"start":22,"end":23,"text":"range"}]},"annotationSets":[{"rank":0,"score":15.324230474235454,"frameElements":[{"name":"Distance","spans":[{"start":22,"end":23,"text":"range"}]}]}]},{"target":{"name":"Substance","spans":[{"start":24,"end":25,"text":"solid"}]},"annotationSets":[{"rank":0,"score":28.085253862140156,"frameElements":[{"name":"Substance","spans":[{"start":24,"end":25,"text":"solid"}]}]}]},{"target":{"name":"Medical_conditions","spans":[{"start":25,"end":26,"text":"tumors"}]},"annotationSets":[{"rank":0,"score":34.09177703115916,"frameElements":[]}]}],"tokens":["By","contrast",",","selectively","inhibiting","BCL-X-L","did","not","suppress","granulopoiesis","but","was","highly","efficacious","in","combination","with","docetaxel","when","tested","against","a","range","of","solid","tumors","."]}
{"frames":[{"target":{"name":"Being_obligated","spans":[{"start":4,"end":5,"text":"have"}]},"annotationSets":[{"rank":0,"score":20.12571061060895,"frameElements":[{"name":"Responsible_party","spans":[{"start":2,"end":4,"text":"BCL-X-L-selective inhibitors"}]}]}]},{"target":{"name":"Capability","spans":[{"start":6,"end":7,"text":"potential"}]},"annotationSets":[{"rank":0,"score":42.89115824489295,"frameElements":[{"name":"Event","spans":[{"start":7,"end":25,"text":"to enhance the efficacy of docetaxel in solid tumors and avoid the exacerbation of neutropenia observed with navitoclax"}]}]}]},{"target":{"name":"Cause_change_of_strength","spans":[{"start":8,"end":9,"text":"enhance"}]},"annotationSets":[{"rank":0,"score":47.138903222607055,"frameElements":[{"name":"Patient","spans":[{"start":9,"end":16,"text":"the efficacy of docetaxel in solid tumors"}]}]}]},{"target":{"name":"Substance","spans":[{"start":14,"end":15,"text":"solid"}]},"annotationSets":[{"rank":0,"score":28.184060308651837,"frameElements":[{"name":"Substance","spans":[{"start":14,"end":15,"text":"solid"}]}]}]},{"target":{"name":"Medical_conditions","spans":[{"start":15,"end":16,"text":"tumors"}]},"annotationSets":[{"rank":0,"score":34.09177703115916,"frameElements":[]}]},{"target":{"name":"Preventing","spans":[{"start":17,"end":18,"text":"avoid"}]},"annotationSets":[{"rank":0,"score":22.98013709143175,"frameElements":[{"name":"Event","spans":[{"start":18,"end":25,"text":"the exacerbation of neutropenia observed with navitoclax"}]}]}]},{"target":{"name":"Statement","spans":[{"start":22,"end":23,"text":"observed"}]},"annotationSets":[{"rank":0,"score":96.94755449251187,"frameElements":[]}]}],"tokens":["Therefore",",","BCL-X-L-selective","inhibitors","have","the","potential","to","enhance","the","efficacy","of","docetaxel","in","solid","tumors","and","avoid","the","exacerbation","of","neutropenia","observed","with","navitoclax","."]}
{"frames":[{"target":{"name":"Education_teaching","spans":[{"start":1,"end":2,"text":"studies"}]},"annotationSets":[{"rank":0,"score":112.65644096268198,"frameElements":[]}]},{"target":{"name":"Reasoning","spans":[{"start":2,"end":3,"text":"demonstrate"}]},"annotationSets":[{"rank":0,"score":43.46524431252732,"frameElements":[{"name":"Arguer","spans":[{"start":1,"end":2,"text":"studies"}]}]}]},{"target":{"name":"Usefulness","spans":[{"start":5,"end":6,"text":"utility"}]},"annotationSets":[{"rank":0,"score":22.843798713886034,"frameElements":[{"name":"Entity","spans":[{"start":6,"end":14,"text":"of this toolkit of selective BCL-2 family inhibitors"}]}]}]},{"target":{"name":"Kinship","spans":[{"start":12,"end":13,"text":"family"}]},"annotationSets":[{"rank":0,"score":21.090108964283065,"frameElements":[{"name":"Relatives","spans":[{"start":12,"end":13,"text":"family"}]}]}]},{"target":{"name":"Capability","spans":[{"start":17,"end":18,"text":"potential"}]},"annotationSets":[{"rank":0,"score":40.14273030751424,"frameElements":[{"name":"Entity","spans":[{"start":16,"end":17,"text":"their"}]}]}]},{"target":{"name":"Cause_to_make_progress","spans":[{"start":19,"end":20,"text":"improved"}]},"annotationSets":[{"rank":0,"score":63.73274505162339,"frameElements":[{"name":"Project","spans":[{"start":20,"end":21,"text":"cancer"}]}]}]},{"target":{"name":"Medical_conditions","spans":[{"start":20,"end":21,"text":"cancer"}]},"annotationSets":[{"rank":0,"score":37.097026595515736,"frameElements":[]}]}],"tokens":["These","studies","demonstrate","the","translational","utility","of","this","toolkit","of","selective","BCL-2","family","inhibitors","and","highlight","their","potential","as","improved","cancer","therapeutics","."]}
